Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results 2021-11-30 22:30
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients 2021-11-15 20:00
RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval 2021-09-13 19:00
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study 2021-06-28 19:00
RedHill Biopharma Announces First Patient Dosed in U.S. Phase 2/3 COVID-19 Outpatient Study with RHB-107 2021-02-17 20:00
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib 2021-01-29 20:26
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals 2021-01-28 22:03
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease 2021-01-06 20:24
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib 2020-12-31 22:38
RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease 2020-11-20 21:00
1